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Abstract
Motivation: Circulating-free DNA (cfDNA) profiling by sequencing is an important minimally inva-
sive protocol for monitoring the mutation profile of solid tumours in cancer patients. Since the
concentration of available cfDNA is limited, sample library generation relies on multiple rounds of
PCR amplification, during which the accumulation of errors results in reduced sensitivity and lower
accuracy.
Results: We present PCR Error Correction (PEC), an algorithm to identify and correct errors in short
read sequencing data. It exploits the redundancy that arises from multiple rounds of PCR amplifica-
tion. PEC is particularly well suited to applications such as single-cell sequencing and circulating
tumour DNA (ctDNA) analysis, in which many cycles of PCR are used to generate sufficient DNA
for sequencing from small amounts of starting material. When applied to ctDNA analysis, PEC sig-
nificantly improves mutation calling accuracy, achieving similar levels of performance to more
complex strategies that require additional protocol steps and access to calibration DNA datasets.
Availability and implementation: PEC is available under the GPL-v3 Open Source licence, and is
freely available from: https://github.com/CRUKMI-ComputationalBiology/PCR_Error_Correction.git.
Contact: ged.brady@cruk.manchester.ac.uk or crispin.miller@cruk.manchester.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Next Generation Sequencing (NGS) of circulating tumour DNA
(ctDNA) from patient blood has the potential to revolutionize cancer
genomics by supporting non-invasive tumour genotyping using
blood-based ‘liquid’ biopsies (Bettegowda et al., 2014; Bratman et al.,
2015; Butler et al., 2015; Diaz and Bardelli, 2014; Diehl et al., 2008;
Heitzer et al., 2015; Kurtz et al., 2015). It is challenging because
ctDNA accounts for as little as 0.01% of the total circulating free
DNA (cfDNA) population (Bettegowda et al., 2014; Bratman et al.,
2015; Newman et al., 2014; Schmitt et al., 2012). Reliable variant de-
tection therefore requires high sequencing depth and many rounds of
amplification. This results in elevated PCR error rates and reduced
mutation calling accuracy. PCR errors arise from a variety of sources
including DNA damage, structure induced template-switching, PCR-
mediated recombination and polymerase misincorporation (Potapov
and Ong, 2017). Together, these lead to a mixture of systematic and
random changes to the amplified molecular sequence.
A number of methodologies have been developed to correct PCR
errors (Kennedy et al., 2014; Newman et al., 2014, 2016; Schmitt
et al., 2012), including Duplex Sequencing (DS) (Kennedy et al.,
2014; Newman et al., 2014; Schmitt et al., 2012), which relies on
barcodes to track the PCR products arising from each DNA frag-
ment. This allows them to be grouped together, and the consensus
between their sequences used to identify and correct errors.
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A recently developed method, iDES (Newman et al., 2016), uses
DS in combination with a second ‘background-polishing’ step that
corrects systematic errors found preferentially within certain sequen-
ces. These have the potential to act as a major confounding factor,
since they can accumulate across specific loci, mimicking a bona
fide variant allele. To do this, iDES uses a background model built
from healthy normal volunteer (HNV) blood samples to identify
‘hotspot’ regions with disproportionately high error rates. Variants
at these loci are then filtered from the results. While a significant
advance, iDES requires high sequencing depths, access to HNV
datasets, and an additional barcoding step. These add cost and com-
plexity to the protocol, and may to reduce the efficiency of library
preparation—particularly undesirable when dealing with limited
amounts of ctDNA material. A similarly sensitive and barcode-free
approach that does not require extremely high-depth sequencing
and external HNV calibration data would therefore further advance
the field.
Here, we describe PCR Error Correction (PEC), a new algorithm
for short-read sequencing data. PEC uses an in silico, barcode-free,
strategy to exploit the redundancy that arises when multiple PCR
amplicons are derived from the same initial DNA fragment. Since
these duplicate reads can confound statistical analyses, they are
typically discarded following alignment, leaving only a single read,
presumed to represent the original cfDNA molecule. Typically, the
terms ‘Sequencing Depth’ and ‘Read Depth’ are used to refer to
the number of overlapping reads before and after de-duplication.
For the purposes of this manuscript, it is useful to define a third
term ‘Duplicate Depth’ to refer to the number of PCR duplicates in
an amplicon cluster.
De-duplication is commonly done using the MarkDuplicates al-
gorithm from Picard (DePristo et al., 2011). MarkDuplicates relies
on the fact that at typical sequencing depths, the likelihood of two
read fragments originating from exactly the same genomic region is
negligible (Methods). It therefore identifies all reads with the same
5’ end (taking into account strandedness) and retains the read with
the highest overall base quality score. While this deals well with
errors resulting from low-quality sequencing, it makes no attempt to
identify high quality reads that nevertheless incorporate PCR errors.
These are then able to propagate to subsequent stages of the analysis
pipeline.
PEC first identifies reads expected to arise from the same initial
starting molecule, using a similar strategy to MarkDuplicates.
However, rather than retaining the read with highest quality score,
it instead uses a local sequence assembly to generate the consensus
sequence for each PCR amplicon set (Fig. 1A). While doing this, it
learns the ‘intrinsic error pattern’ within the data, comprising the
most frequently corrected sequence patterns. This is then used to
identify and correct systematic errors in singleton reads. Here, we
show that this results in equivalent performance to iDES, but with-
out the need for a reference HNV control dataset or an additional
in vitro barcoding step.
2 Materials and methods
2.1 The Pec algorithm
PEC is implemented using the MapReduce-MPI Cþþ library
(Plimpton and Devine, 2011), an open-source implementation of the
Fig. 1. PCR Error Correction (PEC) algorithm. (A) Overview of PEC algorithm pipeline design. DeDuplicates: de-duplication using de novo assembly, in which con-
sensus reads and error k-mer lists are identified. (B) Each PCR duplicate set is independently assembled using a k-mer assembler (based on a de Brujin graph) to
produce a consensus sequence. K-mers that do not match this consensus are flagged as ‘untrusted’, while those that match the consensus are flagged as
‘trusted’. (C) Untrusted k-mers that have never been flagged ‘trusted’ are considered to be error k-mers. These are used to identify errors in reads that are in low
coverage PCR amplicon sets with insufficient duplicate depth to allow a reliable consensus sequence to be generated. (D) In this way, error patterns learnt from
correcting errors in high-coverage PCR amplicon sets are used to correct errors in low-coverage and singleton reads
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MapReduce framework written for distributed memory parallel
machines on top of the open Message Passing Interface (MPI)
library. The overall pipeline can be parallelized across multiple pro-
cessors. It proceeds through several steps (Fig. 1A). The first identi-
fies and groups input reads that are likely to have been amplified
from the same cfDNA molecules. PEC assumes that paired-end
reads aligning to the same genomic location (by 5’ end) are PCR
products derived from the same initial DNA fragment. This is simi-
lar to the approach taken by MarkDuplicates (DePristo et al.,
2011). Locations are identified by aligning reads to the reference
genome using BWA (Li and Durbin, 2009). Each read is represented
by a key-value pair in a MapReduce implementation, with the gen-
omic locations providing the keys. Paired-end reads can then be clus-
tered by a single MapReduce step to produce sets of PCR duplicates,
each with the same genomic locations. It then performs two error
suppression steps. The first, DeDuplicates, applies only to sets with
a relatively high number of PCR duplicates (duplicate depth  5 by
default; note that this refers to the number of read-pairs in the PCR
duplicate set, not the read depth following de-duplication).
A linear sequence assembly algorithm (Grabherr et al., 2011) is
applied to each set to generate its consensus sequence. At each nucleo-
tide in the sequence, the most common allele is selected at the represen-
tative nucleotide. Since the assumption is that all read-pairs mapping
to the same 5’ coordinates are likely to have originated from the same
DNA fragment, this serves to identify and correct PCR errors (Fig. 1B).
In parallel, PEC generates, for each set, the list of k-mers used in
the alignment. These are marked as ‘trusted’ or ‘untrusted’, such
that ‘trusted’ k-mers match the consensus sequences, while
‘untrusted’ k-mers include a potential error residue. Note that error
bases with a low base calling quality score are not considered to be
PCR errors (Phred quality score 20 by default). Since these have al-
ready been identified as potential errors by the scanner software,
PEC leaves them unchanged. Downstream analysis software is then
able to deal with them in the usual way.
The k-mer lists from each PCR-amplicon set are then merged in
order to generate a list of ‘error’ k-mers, comprising all ‘untrusted’ k-
mers that have never been flagged as ‘trusted’. This final list is then
applied only to singleton reads and PCR-amplicon sets with few PCR
duplicates (duplicate depth < 5 by default). For these, the paired-end
read with the highest overall base quality scores is selected as the repre-
sentative cfDNA molecule for each amplicon set. Candidate error bases
are then localized by the intersection of error k-mers (Kelley et al.,
2010) (Fig. 1C) and flagged within the representative reads by lowering
the base quality score for that nucleotide by setting the Phred score to
5 for that base, allowing them to be ignored in subsequent downstream
analyses (Fig. 1D). Since this second step learns error patterns from the
dataset itself, rather than an external reference set, we refer to it as
Intrinsic-Polishing. NGS aligners, such as BWA employ some degree of
compromise between speed and accuracy. The performance of BWA
also begins to degrade for longer reads and/or those with high error
rates (Li and Durbin, 2009). Since the de-duplicated dataset produced
by PEC is significantly smaller, and thus more computationally tract-
able, PEC employs a final step in which the de-duplicated reads are
realigned to the reference genome using the Smith-Waterman C/Cþþ
library (Zhao et al., 2013). This then generates the optimal alignment
for each read. The output of this software is an error-corrected set of
cfDNA reads in bam file format, which can be easily incorporated into
existing NGS data analysis pipelines.
2.2 Likelihood of cfDNA collisions
The strategy employed by PEC is dependent on individual ctDNA
molecules originating from distinct position on the genome. Here
we justify this assumption, using a derivation based on the Birthday
Paradox.
The probability CL of having at least one cfDNA collision at the
given locus can be defined as follows:
CL ¼ 1
ML!
L
ML
 
LML
(1)
where ML represents the expected number of cfDNAs of fixed
length L at a given locus.
In a real experiment, cfDNA fragments are of different lengths.
Since a collision occurs when two cfDNA fragments have identical
start and end points, cfDNA fragments with different lengths cannot
collide. We therefore model the fragment length distribution using a
normal distribution with mean l, r, to produce a distribution for
ML, given the cfDNA depth, D:
M^L ¼ DNðLjl; rÞ (2)
Third, the probability p of having any cfDNA collisions at each
locus with varying length L can be defined as,
p ¼
ð
CLN Ljl; rð ÞdL ¼
X
L
CLN Ljl;rð Þ (3)
With cfDNA prepared using the protocol described in Section
2.3.4, below, typical values of l ¼ 177; r ¼ 20 were determined using
an Agilent Bioanalyzer (data not shown). Using Equation (3), and these
values, p ¼ 0:047 with D¼300X, i.e. 4.7% of the target region is
expected to have cfDNA collisions (Supplementary Fig. S1).
While these are typical values for ctDNA library preparation,
much greater sequencing depths, longer fragments, or less variable
fragment sizes may increase the likelihood of collisions. We there-
fore recommend computing p to confirm that this collision assump-
tion holds, if the library preparation step is expected to generate a
dramatically different distribution. For example, once the cfDNA
depth (as distinct from the sequencing depth) exceeds 500 then the
likelihood of collision becomes prohibitive.
2.3 Evaluation datasets
2.3.1 Dataset 1
We used a previously published cfDNA-seq dataset (Newman et al.,
2016), comprising 4 samples of cfDNAs with simulated ctDNAs
(HD500; Horizon Diagnostics 500), a DNA diagnostic reference stand-
ard consisting of multiple clinically relevant variants with a range of
known allele fractions between 0.94 and 32.5%. The 4 sample repli-
cates were created with 5.0% dilution of acoustically shorn HD500
genomic DNA fragments added to cfDNAs from a healthy donor.
2.3.2 Dataset 2
We simulated the typical cfDNA nucleosomal fragmentation pattern
by applying a double-strand DNA specific endonuclease (EZ
Nucleosomal DNA Prep Kit, Zymo Research, Orange, CA) as per
the manufacturer’s instructions to generate nucleosomal DNA
fragments from both a well-characterized SCLC cell line H446 and
non-cancer control peripheral blood mononuclear cells (PBMCs).
Subsequently we prepared serial dilutions of the nucleosome frag-
mented DNA to generate PBMC/H446 mixtures where the H446
DNA was present at 100, 20, 10, 5 and 0%. These dilution samples
were further NGS whole genome library prepped at final concentra-
tions of 20 and 5 ng to mirror the input cfDNA concentrations from
patient samples for NGS whole genome library preparation. The
whole genome libraries were enriched for 15 genes using a
2382 C.S.Kim et al.
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SureSelectXT Custom DNA Kit (Agilent, Santa Clara, CA, USA) of
15 genes. The enriched DNA libraries were re-amplified using the
KAPA HiFi PCR Kits and Illumina sequencing primers for 13 cycles.
Paired end sequencing was performed for these enriched libraries on
the IlluminaV
R
NextSeq 500 (Illumina, San Diego, CA, USA) benchtop
sequencer with the NextSeq 500/550 Mid Output v2 kit (300 cycles).
2.3.3 Non-Cancer volunteer sample collection
Blood samples for cfDNA analysis were collected in a Cell-FreeTM
DNA BCT tubes (Streck, Omaha, NE). The blood samples were
transferred to the Clinical and Experimental laboratory for process-
ing. Samples were collected from a non-cancer control volunteer
(referred to as HNV or healthy normal volunteer and these were per-
sons recruited from within the CR-UK Manchester Institute that
was not currently suffering or being treated for cancer).
2.3.4 Circulating cell free DNA preparation and quantification
Blood samples collected using Cell-FreeTM DNA BCT tubes (Streck,
Omaha, NE), CellSave, Heparin and EDTA (ethylenediaminetetra-
acetic acid) Vacutainer tubes were used for extraction of circulating
cell free DNA from HNV. Plasma was separated from whole blood
by two sequential centrifugations (each 2000g, 10 min) followed by
upper phase plasma removal and stored at 80C in 2 ml aliquots
(Rothwell et al., 2016). Cell-free DNA (cfDNA) was isolated from
upto 4 ml of double spun plasma using the QIAsymphony in conjunc-
tion with Circulating DNA Kit (Qiagen, Hilden, Germany).
Following isolation, cfDNA yield was quantified using the TaqManV
R
RNase P Detection Kit (Life Technologies) as per manufacturer’s
instructions (Rothwell et al., 2016). Germline DNA (gDNA) was iso-
lated from EDTA whole blood using QIAmp Blood Mini Kit
(Qiagen, Hilden, Germany) as per manufacturer’s instructions.
2.4 Mutation calling using MuTect software
MuTect (Cibulskis et al., 2013), was run with default parameter set-
tings as per the GATK best practices recommendations (https://soft
ware.broadinstitute.org/gatk/best-practices/mutect1.php) with two
additional parameters: ‘-dt NONE -min_qscore 20’.
3 Results
We first evaluated PEC using the reference DNA dataset used by
Newman et al. to evaluate iDES (Newman et al., 2016). These data
were generated by mixing acoustically shorn HD500 genomic DNA
(Horizon Diagnostics) with cfDNA from a healthy donor. The re-
sultant data incorporate a set of known clinically relevant variants
with a wide range of allele frequencies (AF) (0.94%  AF 
32.5%). 4 technical replicates with 5% simulated ctDNA content
were generated.
Comparisons were made between PEC, the Background-
Polishing step of iDES and MarkDuplicates, using each algorithm
as a pre-processing step prior to mutation calling. Since no matching
genomic DNA was available, we were unable to use the standard
GATK pipeline for mutation calling, and instead adopted the ap-
proach used by Newman and colleagues: a Poisson model (Newman
et al., 2016), was used to define the theoretical minimum number of
variant alleles required to detect ctDNAs with 95% confidence. Loci
where the VAF exceeded this detection limit were called as variants.
Target sequences covered a total of 302 620 nucleotides. These
encompassed 239 known SNVs previously shown to be clinically
relevant in NSCLC (Newman et al., 2016) that were not present in
the data, alongside 26 True Positive (TP) SNVs that were present.
Data were evaluated using the widely adopted GATK pipeline,
configured according to the GATK ‘best practices recommendations’
(see Section 2). The performance of the standard pipeline was com-
pared to that achieved by substituting the MarkDuplicates step with
PEC. PEC exhibited improved specificity and positive predictive
value over MarkDuplicates, while matching the specificity and posi-
tive predictive value of the iDES Background-Polishing algorithm
(Fig. 2A–D). Importantly, PEC achieves these improvements with-
out the need to reference an external HNV dataset. As expected,
PEC also suppressed more background errors in regions known to
Fig. 2. Accuracy of each pipeline using Dataset 1. Each point represents an individual dataset. (A) Sensitivity %, (B) Specificity %, (C) Positive predictive value %,
(D) Negative predictive value %, (E) % Target loci (excluding 26 loci with known variations) with VAF ¼ 0, 0<VAF < 1% and VAF > 1% before and after error sup-
pression. (F) Substitution error rate estimated from PEC-DeDuplicates and summarized by nucleotide, and MD represents the error suppression by
MarkDuplicates. MD þ bP represents the error suppression by MarkDuplicates and Background-Polishing. PEC represents the error suppression by DeDuplicates.
PEC þ iP represents the error suppression by DeDuplicates and Intrinsic-Polishing
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be absent of SNVs compared to Extrinsic-polishing (Fig. 2E and
Supplementary Figs S2–S3). These errors included a disproportion-
ate number of G>T and C>T transitions (Fig. 2F), as previously
reported (Newman et al., 2016).
We further evaluated PEC using a second reference dataset gener-
ated by mixing acoustically shorn reference DNA derived from H466
cells with cfDNA from a healthy normal donor (see Section 2). Three
samples were generated at different concentrations along with 100%
HNV cfDNA and 100% H466 DNA were also sequenced and ana-
lyzed using the unmodified GATK best practices workflow
(McKenna et al., 2010), in order to identify SNVs specific to the cell
line. These were then used as a ‘gold standard’ True Positive set for
subsequent analyses. In total, 109 variant alleles were selected as TP
SNVs with VAFs > 25% (Supplementary Fig. S4). Having established
a ground truth for evaluation, comparisons were then made between
PEC and MarkDuplicates, using each algorithm as a pre-processing
step prior to mutation calling using MuTect (Cibulskis et al., 2013).
As before, PEC exhibited increased sensitivity over
MarkDuplicates at all dilutions (Fig. 3). Importantly, 4 SNVs were
only called when Intrinsic-Polishing was employed. In all four cases,
these loci had low, but significant VAF (>2%) in the 100% HNV
cfDNA sample (Supplementary Fig. S5); these variant alleles in the
normal input were removed by Intrinsic-Polishing, leading to the cor-
rect mutation calls at these loci. Finally, we compared the error cor-
rection patterns between the two datasets, to reveal substantial
differences between the two datasets (Supplementary Fig. S6).
Background polishing algorithms that take these error patterns into
account must therefore be able to model different error patterns for
each dataset presented. The intrinsic polishing approach described
here is therefore particularly appealing since it does not require access
to multiple external reference datasets in order to learn these patterns.
Taken together, these data demonstrate that when PEC is incor-
porated into the GATK best practices variant calling pipeline it leads
to improved sensitivity and specificity when used as a direct replace-
ment of MarkDuplicates. It achieves similar performance to the
Background-Polishing approach used by iDES, even though it does
this without recourse to a reference HNV dataset. Since PEC’s con-
tribution is to correct errors by improving the de-duplication step, it
is likely to have general utility beyond the GATK best practices pipe-
line. However, careful validation will be required before adopting it
in each alternate setting. Thus, although the data we present here
demonstrates the utility of PEC in the context of ctDNA data, we
expect it to be widely applicable to other NGS datasets including
those arising from single cell analyses.
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Fig. 3. Comparison of the sensitivity of each pipeline using Dataset 2. 5 dilutions were generated (simulating 0, 5, 10, 20, 100% ctDNA). Sensitivity was calculated
using 109 True Positive loci with VAFs > 25% in the 100% H446 sample. In all panels, each column corresponds to a target locus. (A) VAFs of True Positive loci for
each sample data (see also Supplementary Fig. S4). (B) Mutation calls from each pipeline using MuTect software. White: no mutation call, grey: called by all pipe-
lines, red: called correctly by some pipelines. MD: MarkDuplicates pipeline. PEC: PEC DeDuplicates pipeline. PEC þ iP: PEC DeDuplicates and Intrinsic-Polishing
pipeline. (C) Number of mutation calls and sensitivity. In (A) and (B), each column corresponds to a known SNV and each row represents a simulated ctDNA
sample
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